cip
Drug firm Cipla has received final approval from the US health regulator for lipid regulating Fenofibrate tablets.
The company “has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA),” Cipla said in a BSE filing.
The tablets are generic versions of AbbVie’s Tricor tablets, it added.
“Tricor tablets and generic equivalents had US sales of approximately $307 million for the 12-month period ending October 2016, according to IMS Health,” Cipla said.
The company’s portfolio includes over 1,000 products across a wide range of therapeutic categories.
Shares of Cipla were trading 0.76 per cent up at Rs 570.30 on the BSE.
More Like This
Published on December 19, 2016
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.